Loading stock data…
Lumexa Imaging Holdings, Inc. (LMRI)
$11.54-0.64 (-5.25%)
Market ClosedLast close Sep 8
Lumexa Imaging Holdings, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $252.54M↓ | $267.73M | — | $245.00M↓ | $248.03M |
| Gross Profit | $34.78M↓ | $42.12M | — | $36.60M↑ | $21.57M |
| Operating Income | $4.53M↑ | -$7.47M | — | $10.06M↑ | -$8.40M |
| Net Income | $1.72M↑ | -$28.69M | — | -$7.69M↑ | -$25.06M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomog...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$746.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.96%
Volume
Today's trading volume
293,751
Recent News
Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High?
The consensus price target hints at a 36.9% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Lumexa Imaging (LMRI) Q2 2026 Earnings Call Transcript
Advanced imaging volumes surge as free cash flow hits record $23.1 million.
Lumexa Imaging Holdings Inc (LMRI) (Q2 2026) Earnings Call Highlights: Record Advanced Modality ...
Lumexa Imaging Holdings Inc (LMRI) posts strong Q2 with record free cash flow, 23.2% PET volume growth, and a strategic New York JV, despite margin pressure from public company costs.
Lumexa Imaging Q2 Earnings Call Highlights
Lumexa Imaging (NASDAQ:LMRI) reported second-quarter revenue growth, higher advanced-imaging volumes and a return to profitability, while narrowing its full-year adjusted EBITDA outlook and reiterating revenue and adjusted earnings-per-share guidance. Chief Executive Officer Caitlin Zulla said the
Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway
Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth.